{"filings":[{"id":1038998,"accession_number":"0001493152-26-028615","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2026-06-15T12:01:16+00:00","items":["8.01","9.01"],"status":"ready","headline":"AIM ImmunoTech regains NYSE American listing compliance after equity deficiency resolved","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received NYSE American notice on June 12, 2026 that it resolved stockholders' equity deficiencies under Sections 1003(a)(i)-(iii).","Raised ~$8.5M total through warrant exercises and stock sales: $3.5M (May 7 warrant inducement), $2.4M (May 21 placement), $2.6M (June 10 placement).","Issued over 10M shares and warrants; believes stockholders' equity now exceeds $6M minimum requirement.","\".BC\" indicator to be removed from trading symbol (AIM); company removed from NYSE American noncompliant list."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1000317,"accession_number":"0001493152-26-028283","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2026-06-11T20:15:23+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"AIM ImmunoTech prices $2.65 million registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company issued 2,554,119 registered shares and 771,503 unregistered shares at $0.5189 per share for gross proceeds of ~$2.65M.","Also issued pre-funded warrants for 1,782,616 shares at $0.001 exercise price and Class J warrants for 10,216,476 shares at $0.5189.","Offering includes placement agent warrants for 306,494 shares at $0.6486 per share; Ladenburg Thalmann acted as placement agent.","Net proceeds will fund clinical trial activities, manufacture of clinical drug supply, and working capital.","Closing expected on or about June 10, 2026, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":974796,"accession_number":"0001493152-26-028129","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2026-06-10T20:59:15+00:00","items":["5.03","9.01"],"status":"ready","headline":"AIM ImmunoTech amends bylaws: majority of votes cast standard for non-director proposals","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Amendment to Bylaws effective June 9, 2026, changing voting standard for proposals other than director elections.","New standard: affirmative vote of majority of votes cast (for/against only), excluding abstentions and broker non-votes.","Previous standard required majority of shares present or by proxy and entitled to vote.","Amendment filed as Exhibit 3.1 and incorporated by reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":843918,"accession_number":"0001493152-26-027210","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2026-06-04T13:00:38+00:00","items":["7.01","9.01"],"status":"ready","headline":"AIM ImmunoTech highlights Ampligen preclinical data for Ebola preparedness","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Video discusses Ampligen as prophylactic/early-onset treatment for Bundibugyo Ebola strain with no approved therapies.","Preclinical findings: 100% protective survival with early Ampligen administration in lethal Ebola mouse model.","Ampligen has orphan drug designation from FDA and EMA for Ebola virus disease.","Updated Ebola-focused corporate presentation available on company website.","CEO Thomas Equels noted urgent need for therapeutic in ongoing outbreak."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":570716,"accession_number":"0001493152-26-024760","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2026-05-21T15:31:14+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"AIM ImmunoTech prices $2.4M registered direct offering of 7.5M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 7,519,351 shares at $0.325 per share; gross proceeds ~$2.4M before expenses.","Concurrent private placement of Common Warrants to purchase up to 15,038,702 shares at $0.325.","Warrants exercisable after stockholder approval, expire 5 years later; potential additional $4.9M.","Closing expected May 21, 2026; company expects at least $6M in stockholders' equity post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":508876,"accession_number":"0001493152-26-024353","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2026-05-19T12:03:26+00:00","items":["1.01","2.02","2.03","7.01","9.01"],"status":"ready","headline":"AIM ImmunoTech increases stockholder equity to $2.1M, extends note maturity to June 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholder equity rose to ~$2.1M as of March 31, 2026, from a deficit of ~$9.8M at Dec 31, 2025 (+$11.9M).","Entered Amendment #2 with Streeterville Capital, extending promissory note maturity to June 30, 2027; outstanding balance ~$1.68M.","Extension fee of $10,000 added to note balance; additional equity-generating funds raised since March 31.","CEO states amendment enhances capital allocation flexibility for pancreatic cancer program and other initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":78283,"accession_number":"0001493152-26-022891","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2026-05-14T12:45:38+00:00","items":["7.01","9.01"],"status":"ready","headline":"AIM ImmunoTech reports Ampligen pancreatic cancer data: OS improvement 7.2 months vs historical controls","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Named Patient Program shows PFS 12.6 months (+4 mo) and OS 19.7 months (+7.2 mo) vs historical controls.","DURIPANC Phase 2 with AstraZeneca's Imfinzi interim data suggests improved QoL; mid-2026 report due June.","Stratified by Neutrophil/Lymphocyte ratio <4.5: PFS 17.7 months (+9.1 mo) and OS 34.8 months (+22.3 mo).","CA 19-9 <1000 subgroup: PFS 13.1 months (+4.5 mo) and OS 24.1 months (+11.6 mo)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":41121,"accession_number":"0001493152-26-022499","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2026-05-12T20:27:44+00:00","items":["3.02"],"status":"ready","headline":"AIM ImmunoTech closes warrant inducement, raises ~$3.6M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders exercised Existing Warrants for 7,451,920 shares at reduced price of $0.48 per share.","Company issued new Class H Inducement Warrants to purchase up to 14,903,840 shares at $0.60 per share, exercisable for 5 years.","Gross proceeds from warrant exercise were approximately $3.6 million; placement agent fees of ~$285K (8% of gross) paid.","Placement agent Ladenburg Thalmann also received warrants to purchase 6% of the shares issued (Placement Agent Warrants).","Securities were issued under Section 4(a)(2) exemption; not registered under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99961,"accession_number":"0001493152-26-021863","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"AIM ImmunoTech expects ~$4.2M gross from warrant inducement at $0.48/share; new warrants at $0.60","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing warrants from May 2024, Sep 2024, Jul 2025 exercised at reduced exercise price of $0.48; gross proceeds ~$4.2M if fully exercised.","New Class H inducement warrants at 200% coverage; exercise price $0.60, 5-year term, subject to stockholder approval.","Placement agent: Ladenburg Thalmann; 8% cash fee, 6% warrant coverage, plus 0.75% management fee.","Proceeds to be used for working capital and general corporate purposes.","Company to call stockholder meeting within 75 days post-closing to approve issuance of Inducement Warrant Shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99960,"accession_number":"0001493152-26-016179","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"AIM ImmunoTech amends ATM agreement to remove $3M cap on share sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 1 to Equity Distribution Agreement with Maxim Group removes the prior $3,000,000 limit on shares sold.","Company's common stock continues to be offered at-the-market under existing shelf registration statement (Form S-3).","A prospectus supplement was filed to increase the number of shares available for sale in the offering.","Maxim Group remains the exclusive sales agent for the at-the-market offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116274,"accession_number":"0001493152-26-009190","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"AIM ImmunoTech closes rights offering raising $1.8M; issues Series G Preferred and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of approximately $1.8 million from 1,842 units in rights offering.","Each unit consists of one share of Series G Convertible Preferred Stock convertible at $1.00 per share.","Each unit includes 2 Class G Warrants exercisable at $1.00 per share, expiring in five years.","Series G Preferred has limited voting rights and pari passu liquidation preference with common stock.","Conversion capped at 4.99% beneficial ownership, adjustable to 9.99% with notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116273,"accession_number":"0001493152-26-005208","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Positive interim Phase 2 data for Ampligen+Imfinzi in metastatic pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["18 patients enrolled in DURIPANC Phase 2; combination well-tolerated with only two grade 3 immune-related AEs.","Promising PFS and OS from Phase 1 continue in Phase 2; detailed data expected for publication later this year.","Patients report high quality of life during treatment despite advanced PDAC.","Immune profiling shows coordinated activation of innate and adaptive immune responses by Ampligen+durvalumab.","AIM holds US patent for Ampligen+anti-PD-L1 combination to 2039; orphan drug designations in US and EU."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116272,"accession_number":"0001493152-26-002728","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AIM ImmunoTech adjusts warrant exercise price to $1.439, increases warrant count to 5.56M each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Triggered by a 1-for-1,000 share stock dividend on January 13, 2026.","Class E and Class F warrant exercise price reduced to $1.439 per share.","Number of outstanding warrants in each class increased to 5,561,125.","VWAP during evaluation period fell below floor price, ending further adjustments.","Reduction is permanent under warrant terms; no further triggers possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116271,"accession_number":"0001493152-26-001898","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AIM ImmunoTech furnishes January 2026 corporate presentation","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation filed as Exhibit 99.1 on Form 8-K dated January 12, 2026.","No financial results or operational milestones disclosed in the filing.","Cautionary statements reiterate risks of Ampligen development across viral, cancer, and immune indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132736,"accession_number":"0001493152-25-028156","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AIM ImmunoTech holds 2025 annual meeting; all director nominees elected, say-on-pay advisory approved by votes cast","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected with majority of votes cast; broker non-votes of 833,173 on each.","Ratification of BDO USA as auditor approved: 1,104,780 for, 29,754 against, 9,849 abstain.","Advisory say-on-pay approved by 193,668 for vs 115,337 against, but failed due to 833,173 broker non-votes.","Advisory vote on frequency selected 1 year (284,856 votes), consistent with board recommendation.","Quorum of 41.4% (1,144,383 shares) present; 2,764,188 shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132735,"accession_number":"0001493152-25-024156","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"AIM ImmunoTech raises $2.5M via unsecured promissory note with Streeterville Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Net proceeds of $2,500,000 from $3,301,250 note after $781,250 OID and $20,000 transaction costs.","Note bears 10% interest compounded daily, matures in 24 months from November 18, 2025.","Investor may redeem up to $250,000 per month starting 6 months after closing.","Mandatory prepayment of 12.5% of any future financing proceeds until note is paid.","Note is unsecured; events of default include cross-default and bankruptcy provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132734,"accession_number":"0001493152-25-020102","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"AIM ImmunoTech files amended and restated certificate of incorporation","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed amended and restated Certificate of Incorporation as Exhibit 3.1(i) effective October 29, 2025.","No details on specific amendments provided in the filing; changes unclear.","Certificate supersedes all prior individual exhibits containing portions of charter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132733,"accession_number":"0001493152-25-018583","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AIM ImmunoTech furnishes investor presentation for Maxim Growth Summit 2025","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation furnished for Maxim Growth Summit 2025 taking place Oct 22-23, 2025 in New York.","No material new financial or operational data disclosed; presentation contains forward-looking statements.","Highlights Ampligen development for viral diseases, cancers, and immune-deficiency disorders.","Filing states information is furnished, not filed, and not incorporated by reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149266,"accession_number":"0001641172-25-021762","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"AIM ImmunoTech closes $8.0M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $8.0M from offering of 2M shares (or pre-funded warrants) and Class E/F warrants at $4.00 per share.","Class E warrants expire in 5 years, Class F in 18 months; exercise price $4.00 per share.","Maxim Group LLC acted as sole placement agent for the offering.","Offering closed July 31, 2025; registration statement on Form S-1 effective July 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149265,"accession_number":"0001493152-25-011441","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AIM ImmunoTech reports positive mid-year Phase 2 data for Ampligen+Imfinzi in pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No grade ≥2 immune-related or systemic toxicities reported across 14 enrolled patients.","3 of 14 patients (21%) had PFS >6 months; 3 additional patients not yet progressed at cutoff.","Of 11 evaluable patients, 7 (64%) achieved overall survival >6 months.","Combination of Ampligen (rintatolimod) and AstraZeneca's Imfinzi (durvalumab) studied post-FOLFIRINOX.","Final analysis pending immune-monitoring data from paired biopsies and blood samples."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168292,"accession_number":"0001641172-25-015861","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"AIM ImmunoTech gets second NYSE American noncompliance notice for negative $3.9M equity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE American warned AIM on June 17, 2025 for failing minimum stockholders' equity: negative $3.9M as of March 31, 2025.","Company has losses in five most recent fiscal years; similar warning was issued on Dec 17, 2024.","Compliance plan accepted Feb 26, 2025; AIM has until June 11, 2026 to regain compliance.","AIM common stock recommenced trading June 17 under symbol 'AIM'; notice does not affect trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168291,"accession_number":"0001641172-25-014899","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["3.01","5.03","8.01","9.01"],"status":"ready","headline":"AIM ImmunoTech completes 1-for-100 reverse split; regains NYSE American listing compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-100 ratio effective June 12, 2025; new CUSIP 00901B303.","NYSE American withdrew delisting determination; trading resuming June 17, 2025 under symbol AIM.","Stock traded on OTC Pink (AIMID) during suspension; now reinstated on NYSE American.","Reverse split authorized by stockholders Apr 30, 2025; Board fixed ratio May 29, 2025.","Cash paid for fractional shares post-split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168290,"accession_number":"0001641172-25-007954","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"AIM ImmunoTech shareholders approve reverse stock split up to 1-for-100","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held April 30, 2025; proposal passed with 23,041,332 for, 19,942,903 against.","Board may enact reverse split at any ratio up to 1-for-100 at its sole discretion.","Split intended to increase per-share price; no specific ratio or effective date announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168289,"accession_number":"0001641172-25-002858","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"AIM ImmunoTech receives NYSE American delisting notice for low stock price; plans appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice on April 4, 2025 from NYSE American of suspension and delisting under Section 1003(f)(v) due to low selling price.","Company will appeal the delisting determination to the Listing Qualifications Panel; no guarantee of success.","Common stock expected to begin trading on the Pink Open Market on April 7, 2025.","Trading on NYSE American has been suspended effective April 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168288,"accession_number":"0001641172-25-002702","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"AIM ImmunoTech enters ATM offering agreement for up to $3M common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Equity Distribution Agreement with Maxim Group LLC for at-the-market offering of up to $3M common stock.","Currently limited to selling $663,329 due to Form S-3 General Instruction I.B.6; registration statement not yet effective.","Maxim receives 3.0% commission on gross proceeds; expense reimbursement up to $50,000 initial, $5,000 quarterly.","Net proceeds to be used for working capital and general corporate purposes.","Agreement may be terminated by either party on 15 days' notice or after 24 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185475,"accession_number":"0001493152-25-008617","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NYSE American accepts AIM ImmunoTech's plan to regain listing compliance; deadline June 11, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Plan accepted under Sections 1003(a)(ii) and 1003(a)(iii) of NYSE American Company Guide.","AIM has until June 11, 2026 to meet minimum stockholders' equity requirements.","CEO Thomas K. Equels expressed confidence in executing the strategy.","Company continues oncology and antiviral pipeline development alongside compliance efforts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185474,"accession_number":"0001493152-25-008282","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"AIM ImmunoTech appoints David Chemerow as independent director; reduces stockholder meeting quorum to 33 1/3%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Chemerow appointed as independent director, effective February 24, 2025.","Chemerow brings 40+ years of finance, accounting, and operations leadership experience; former CFO of Comscore.","Bylaws amended to reduce quorum for stockholder meetings from 40% to 33 1/3%.","Chemerow will be compensated same as other directors; serves until 2025 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185473,"accession_number":"0001493152-25-005802","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Erasmus MC Safety Committee approves Phase 2 study of Ampligen + Imfinzi for late-stage pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 safety data showed combination generally well-tolerated with no severe adverse events or dose-limiting toxicities.","Phase 1 safety data showed combination generally well-tolerated with no severe adverse events or dose-limiting toxicities.","CEO Tom Equels and Prof. van Eijck discussed milestone in Virtual Investor segment.","Study is investigator-initiated, single-center at Erasmus MC in the Netherlands."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185472,"accession_number":"0001493152-25-005800","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AIM ImmunoTech delays S-1 offering until after filing 2024 Annual Report","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Will not proceed with S-1 offering until after filing Form 10-K for fiscal year ended December 31, 2024.","Announcement made via press release on February 11, 2025.","No new financial details or offering terms disclosed; timing remains uncertain.","Company states no material impact on operations from the delay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185471,"accession_number":"0001493152-25-005310","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aim ImmunoTech plans combo study of Ampligen and FluMist for avian flu","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plans to file IND for trial combining Ampligen with AstraZeneca's FluMist to target avian influenza.","Prior UAB clinical data showed Ampligen + FluMist induced cross-reactive antibodies against H5N1, H7N9, H7N3.","Pre-clinical work demonstrated 50-100% survival in mice challenged with H5N1 variants vs. 0-60% naive controls.","AIM has engaged CRO Amarex for IND application and study management; seeking government/industry grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185470,"accession_number":"0001493152-25-004948","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AIM ImmunoTech gets safety committee nod for Phase 2 of Ampligen + Imfinzi in pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Safety committee approved Phase 2 based on Phase 1 data: no severe adverse events or dose-limiting toxicities.","Phase 2 enrollment expected to commence imminently; up to 25 patients to be enrolled.","Combination therapy uses AIM's Ampligen and AstraZeneca's Imfinzi for late-stage pancreatic cancer.","Phase 1 data showed combination generally well-tolerated; some patients had stable disease for 15+ months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202060,"accession_number":"0001493152-24-051835","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AIM ImmunoTech officers Equels and Rodino voluntarily forego 2024 cash bonuses to fund Ampligen R&D","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Thomas K. Equels and Peter W. Rodino III notified the Compensation Committee they will forgo their 2024 cash bonuses.","The voluntary waiver is intended to help AIM focus financial resources on Ampligen R&D activities.","The Compensation Committee then determined that neither will receive a cash bonus for 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202059,"accession_number":"0001493152-24-051088","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AIM ImmunoTech annual meeting elects one dissident nominee, say-on-pay fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nancy K. Bryan, Thomas K. Equels, Ted D. Kellner (dissident), and William M. Mitchell elected directors.","Dissident nominee Kellner won a seat; company-nominees Appelrouth, Chioini, Deutsch, Sweeney were not elected.","Say-on-pay advisory vote failed: 8.5M for, 21.7M against, 3.7M abstain.","Ratification of BDO USA as auditor passed with 23.7M for vs. 1.8M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202058,"accession_number":"0001493152-24-050433","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"AIM ImmunoTech receives NYSE American delisting notice for stockholders' equity deficit","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' deficit of $2.9M as of Sept 30, 2024; fails $4M and $6M equity thresholds.","Must submit compliance plan by Jan 10, 2025; cure period until June 11, 2026.","Stock to trade with \".BC\" designation while below compliance; no immediate impact on listing.","Company has reported net losses in five most recent fiscal years.","If plan not accepted or compliance not regained, delisting proceedings may commence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202057,"accession_number":"0001493152-24-047999","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"AIM ImmunoTech adopts Cash Conservation Plan; independent directors paid entirely in stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Independent directors will receive 100% of board compensation in shares, effective immediately; no cash compensation.","Twice-monthly stock grants valued at closing price on last trading day before grant.","Previously announced CEO Thomas Equels and COO Peter Rodino agreed to reduce cash salaries by $200k and $50k, effective Sept 11, 2024.","Company encourages shareholders to vote for incumbent directors at Dec 17, 2024 annual meeting on WHITE proxy card."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202056,"accession_number":"0001493152-24-039011","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"AIM ImmunoTech raises $1.26M via registered direct offering and warrant private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issues 4,653,036 shares at $0.27 each; gross proceeds ~$1.26M before placement agent fees.","Concurrent private placement of Class C and D warrants to purchase up to 4,653,036 shares each, exercise price $0.28.","Warrants exercisable six months after issuance; Class C expire 18 months later, Class D 5 years later.","Maxim Group acts as placement agent with 8% cash fee; 90-day lock-up for officers and directors.","Company restricted from equity issuances for 60 days (except ATM after 30 days) and no variable rate transactions for 120 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218101,"accession_number":"0001493152-24-036060","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["3.02","5.02","9.01"],"status":"ready","headline":"AIM ImmunoTech amends CEO/COO employment: CEO salary $650k plus $100k stock","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Equels: cash salary reduced to $650,000, plus $100,000 in restricted shares for one year ending Sept 11, 2025.","COO Rodino: base salary $375,000 plus $50,000 in shares; period corrected to one year ending Aug 12, 2025.","Amendment corrects prior duration error in August 2024 compensation changes for both officers.","Shares valued at 100% of Sept 10, 2024 closing price; compensation committee approved the revisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218100,"accession_number":"0001493152-24-029822","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"AIM ImmunoTech adopts amended bylaws following Delaware Supreme Court ruling","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company adopted Restated and Amended Bylaws on July 31, 2024.","Amendments remove or revise advance notice provisions deemed unenforceable by Delaware Supreme Court in Kellner v. AIM ImmunoTech Inc.","For the 2024 annual meeting, stockholder notices of nominations or business must be delivered by September 13, 2024.","Other conforming and clarifying changes were made to prior bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218099,"accession_number":"0001493152-24-027869","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Delaware Supreme Court rules on AIM Immunotech bylaw challenge; election unchanged","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Delaware Supreme Court affirmed in part, reversed Court of Chancery post-trial decision in Kellner v. AIM Immunotech.","Court found one bylaw facially invalid and others unenforceable, but no remedy because Kellner's conduct was deemed deceptive.","Results of 2023 Annual Meeting (director election) remain unchanged as reported on Jan 10, 2024.","Company reviewing opinion and will amend its bylaws to comply with rulings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238050,"accession_number":"0001493152-24-022329","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"AIM ImmunoTech raises $2.0M in registered direct offering and warrant placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issues 5,640,958 shares at $0.363/share for gross proceeds of ~$2.0M to a single institutional investor.","Concurrent private placement of Class A and B warrants to purchase up to 5,640,958 shares each, exercisable at $0.363.","Class A warrants exercisable after 6 months, expire 18 months later; Class B warrants expire 5 years after exercise date.","Officers and directors agree to 90-day lock-up; company restricted from issuing equity for 60 days (30-day ATM exception).","Maxim Group LLC serving as placement agent with 8% cash fee and expense reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255529,"accession_number":"0001493152-24-007230","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"AIM ImmunoTech raises $2.5M via private placement of 10% unsecured promissory note","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Original principal $3,301,250; $781,250 OID and $20,000 legal fees deducted, net proceeds $2,500,000.","Note bears 10% interest compounded daily, matures 24 months from February 16, 2024.","Investor may redeem up to $250,000 per month starting 6 months after closing, with notice.","Prepayment permitted; events of default include non-payment, incorrect reps, cross-default, bankruptcy.","Default interest rate is lesser of 22% or maximum allowed by law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255528,"accession_number":"0001493152-24-005649","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2024-02-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AIM ImmunoTech reports positive Phase 2 topline results for Ampligen in post-COVID fatigue","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint (PROMIS Fatigue Score at week 13) not significant; Ampligen showed lower fatigue at multiple timepoints vs placebo.","Secondary and ad hoc analyses showed differences in PROMIS Fatigue Score reaching or approaching statistical significance at several timepoints.","Six-Minute Walk Test: Ampligen group had higher distance traveled at week 13 vs placebo.","Safety: Ampligen generally well tolerated; no severe TEAEs or deaths. 15% mild treatment-related TEAEs in Ampligen group.","Study enrolled 80 subjects (40 per arm); 82.5% completed (90% Ampligen, 75% placebo)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255527,"accession_number":"0001493152-24-003779","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AIM ImmunoTech furnishes supplemental data deck on pancreatic cancer Early Access Program","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Deck titled 'Pancreatic Cancer Early Access Program Supplemental Data Q1 2024' furnished as Exhibit 99.1.","Data posted on the 'Investors' section of the company's website.","No specific clinical results or financial figures disclosed in the 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255526,"accession_number":"0001493152-24-001918","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AIM ImmunoTech shareholders reject advisory compensation vote; directors elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Four director nominees elected: Appelrouth (6.95M for), Bryan (10.52M), Equels (10.29M), Mitchell (6.68M).","Ratification of BDO USA as auditor passed: 18.18M for, 0.60M against, 1.63M abstain.","Non-binding advisory vote on executive compensation failed: 4.58M for, 7.32M against.","Frequency of compensation vote: 1 year selected with 10.46M votes; board set annual vote.","Broker non-votes of 7.98M on Proposals 1, 3, and 4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255525,"accession_number":"0001493152-24-001905","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AIM ImmunoTech opens enrollment in Phase 1b/2 trial of Ampligen + Imfinzi for pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment open at Erasmus MC for DURIPANC study combining Ampligen + AstraZeneca's Imfinzi; dosing expected soon.","Phase 1b portion will enroll up to 18 subjects; Phase 2 up to 25 patients with metastatic pancreatic ductal adenocarcinoma.","Ampligen dose escalation from 200 mg to 400 mg IV twice weekly; durvalumab 1500 mg IV every 4 weeks for up to 48 weeks.","Primary objectives: safety in Phase 1b, clinical benefit rate in Phase 2.","AIM recently received a U.S. patent for using Ampligen in combination with an anti-PD-L1 antibody."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272984,"accession_number":"0001493152-23-041393","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AIM Immunotech files 8-K with Q3 2023 update presentation; no specific data available in filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing includes a company presentation as Exhibit 99.1 titled Q3 2023 Update Conference Call and dated November 15, 2023.","Presentation is furnished under Regulation FD and not filed; no financial or operational details are provided in the 8-K body.","No specific earnings, revenue, EPS, or guidance figures are available from the furnished content as seen in the filing.","Ticker: AIM; stock listed on NYSE American."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272983,"accession_number":"0001493152-23-039836","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AIM Immunotech presents ovarian cancer chemoimmunotherapy data at SITC 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Poster presented at SITC 38th Annual Meeting (Nov 1-5, 2023) by UPMC collaborators.","Data on combination intraperitoneal chemoimmunotherapy for recurrent platinum-sensitive ovarian cancer.","Study demonstrates T-cell chemotactic locoregional response per poster title.","Poster available on company's investor website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289827,"accession_number":"0001493152-23-034740","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"AIM ImmunoTech enters amended research agreement with Roswell Park for Ampligen® studies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement covers three clinical trials: melanoma, prostate cancer, triple-negative breast cancer.","AIM will supply Ampligen® to Roswell Park for research projects at no cost.","Term is three years from September 20, 2023, or until completion of research.","Research may be funded by external entities (NIH, DOD, foundations); no financial terms disclosed.","AIM retains ownership of Ampligen® and pre-existing IP; jointly developed inventions are shared."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289826,"accession_number":"0001493152-23-033396","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2023-09-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AIM ImmunoTech to present Ampligen oncology data at Roswell Park symposium","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Chris McAleer, Ph.D., Scientific Officer, will present at the Marie Sklodowska-Curie Symposium on Cancer Research and Care at Roswell Park.","Company also sponsors the symposium; presentation titled 'Rintatolimod (Ampligen): Overview of Ampligen’s Clinical Progress in Oncology'.","No new clinical results or financial data disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289825,"accession_number":"0001493152-23-029891","cik":946644,"company_name":"AIM ImmunoTech Inc.","ticker":"AIM","form_type":"8-K","filed_at":"2023-08-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AIM ImmunoTech rejects stockholder Kellner's director nominations as invalid","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board determined notice from Ted D. Kellner nominating himself, Todd Deutsch, and Robert L. Chioini fails to comply with company bylaws.","Company's legal counsel sent letter detailing numerous disclosure deficiencies, including false statements about nominee qualifications and undisclosed agreements.","All three nominees concealed adverse proxy advisor recommendations; each falsely answered 'No' on related questionnaire item.","Notice fails to disclose agreements with individuals involved in prior attempted board takeover, including a convicted felon.","Company will disregard nominations at 2023 annual meeting; deadline for valid notice has passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6756014.762902019,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-08-23T23:59:59+00:00|289825"}